FIFTH AMENDMENT TO LOAN AGREEMENTLoan Agreement • May 1st, 2023 • LumiraDx LTD • Pharmaceutical preparations • New York
This FIFTH AMENDMENT TO LOAN AGREEMENT (this “Fifth Amendment”), dated and effective as of March 1, 2023 (the “Fifth Amendment Effective Date”), is made by and among LUMIRADX INVESTMENT LIMITED, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (as “Borrower” and a Credit Party), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (“BPCR”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (“BioPharma Credit” and together with BPCR, the “Lenders” and each a “Lender”).
Between:Royalty Agreement • May 1st, 2023 • LumiraDx LTD • Pharmaceutical preparations
AMENDMENT 2 to GRANT AGREEMENT AMENDMENT SUMMARY & SIGNATURE PAGEGrant Agreement • May 1st, 2023 • LumiraDx LTD • Pharmaceutical preparations
This Amendment includes and incorporates into the Agreement by this reference: This Amendment Summary & Signature Page and:-Attachment A-2-Supplemental Global Access Commitment Agreement (Attachment C-2)-Investment Document (date updated September 16, 2022)-Budget (date updated September 16, 2022)
